We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » NICE Rejects Celgene’s Revlimid; Drugmaker Touts Phase III Data in Myeloma Study
NICE Rejects Celgene’s Revlimid; Drugmaker Touts Phase III Data in Myeloma Study
July 11, 2013
The UK’s cost-benefit agency has ruled against recommending Celgene’s blockbuster myeloma drug Revlimid for treating myelodysplastic syndromes (MDS), noting uncertainty about the drug’s ability to improve survival rates in patients with MDS abnormalities.